Biossil aims to revive failed drug candidates using AI. This initiative marks a significant shift in drug development. The startup, founded by University of Toronto alumni, focuses on transforming how pharmaceuticals are developed.
Biossil has a portfolio of 10 drug candidates. Two of these are currently in advanced clinical trials. The company has raised about US$70 million to date, showcasing investor confidence in its mission.
Anthony Mouchantaf, a key figure at Biossil, stated, “We’ve very quietly become the most advanced drug developer of this AI era, bar none.” This claim highlights the company’s ambition and progress in the field.
Meanwhile, legal troubles surround Franklyn Nolan, accused of multiple drug-related offenses. He faces charges including possession of heroin and cocaine. Police found about 400 grams of heroin and more than 100 grams of cocaine at his home. Officials estimate the street value of these drugs at around $60,000.
Nolan’s drug-trafficking trial faced complications when he dismissed his lawyer. He stated, “(Caven) is a good lawyer; it’s just a disagreement (between us).” This development raises questions about the future of his defense.
In another incident, Mikaela Laforge was charged with Operation While Impaired – Drug and/or Alcohol after hitting a utility pole at 9 p.m. She was arrested and transported to the hospital for a blood sample analysis. None of the allegations against her have been tested in court—she is considered innocent until proven guilty.
The landscape of drug development continues to evolve with companies like Biossil pushing boundaries through technology. Yet, challenges persist in the realm of drug trafficking and related legal issues that impact public perception and policy.
About The Author
